What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · EXEL, MRNA, XBI

Biotech M&A frenzy kicks off with $10.6B deal — target the next takeover candidates

GSK is buying Nuvalent for $10.6 billion to expand its lung cancer treatments. This highlights a massive wave of pharmaceutical companies buying up smaller biotech firms to replenish their drug pipelines.

Idea

Large drugmakers are facing patent expirations and desperately need new drugs to sell. GSK's $10.6 billion purchase of Nuvalent proves they are willing to pay massive premiums to get them. As this deal-making frenzy continues, other mid-sized biotech firms with successful cancer or obesity treatments could become the next takeover targets, making them attractive investments right now.

Key details

EXEL MRNA XBI1D#biotech#M&A#momentum

Community

Upvotes

Views

Copies

Cosigns

News sources

GSK Agrees to Buy Nuvalent for $10.6 Billion — Bloomberg
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT — CNBC

Related ideas

Massive $5.4 billion floods into chip stocks — ride the wave on SOXX
Trillion-dollar chip giant SK Hynix hits Wall Street — ride the IPO momentum
Tesla finally delivers on its decade-old promise — ride the AI momentum into Nvidia instead

EXEL trade ideas
MRNA trade ideas
XBI trade ideas
Latest market news